Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Cancer Research UK

- PMLiVE

Novo Nordisk and Vivtex partner in deal worth up to $2.1bn

The companies aim to develop next-generation oral medicines for obesity and diabetes

- PMLiVE

Novo Nordisk and Aspect Biosystems expand collaboration on diabetes research

The companies are working together on cellular medicines to boost, replace or repair biological functions

- PMLiVE

Eli Lilly shares promising phase 3 results for once-weekly insulin candidate efsitora alfa

The company is planning to submit regulatory applications for the candidate by the end of the year

regeneron headquarters

Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn

The candidate is being evaluated in a phase 3 obesity trial and phase 2b diabetes study

- PMLiVE

BeiGene’s Tevimbra approved by FDA for first-line oesophageal cancer use

Oesophageal squamous cell carcinoma accounts for nearly 90% of all oesophageal cancers

- PMLiVE

LEO pharma gains EU rights to Junshi Biosciences’ PD-1 inhibitor toripalimab

The drug was approved by the EC last year to treat nasopharyngeal and oesophageal cancer

- PMLiVE

Eli Lilly announces $3bn expansion to US injectables manufacturing facility

The investment will help Lilly meeting the growing demand for its diabetes and obesity medicines

- PMLiVE

Sanofi unveils plans to build €1bn insulin production base in China

The site will focus on serving the insulin medication needs of local diabetic patients

- PMLiVE

BeiGene’s Tevimbra approved by EC for first-line gastric and oesophageal cancer use

Gastric cancer is the fifth leading cause of cancer-related deaths globally and oesophageal cancer is the sixth

- PMLiVE

BeiGene’s Tevimbra recommended by CHMP for gastric and oesophageal cancer

Gastric cancer is the fifth leading cause of cancer-related deaths globally, while oesophageal cancer is the sixth

- PMLiVE

Common antidiabetic drug metformin found to slow growth of precancerous cells

The findings suggest that the drug could be used to manage squamous oesophageal cancer risk

- PMLiVE

Eli Lilly’s once-weekly insulin candidate shows promise in late-stage diabetes trials

It is hoped that a once-weekly treatment option could improve adherence rates

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links